BR112023025850A2 - Inibidores da nicotinamida ripk1 - Google Patents

Inibidores da nicotinamida ripk1

Info

Publication number
BR112023025850A2
BR112023025850A2 BR112023025850A BR112023025850A BR112023025850A2 BR 112023025850 A2 BR112023025850 A2 BR 112023025850A2 BR 112023025850 A BR112023025850 A BR 112023025850A BR 112023025850 A BR112023025850 A BR 112023025850A BR 112023025850 A2 BR112023025850 A2 BR 112023025850A2
Authority
BR
Brazil
Prior art keywords
nicotinamide
ripk1
inhibitors
ripk1 inhibitors
compounds
Prior art date
Application number
BR112023025850A
Other languages
English (en)
Inventor
Ciaran O'reilly
Andrew Kinsman David
Euan Fordyce
Hannah Dexter
Patrick Stambuli James
Patrick Cusack Kevin
Anastasia Argiriadi Maria
Zeller Hoemann Michael
Sami Osman
St Gallay Steve
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112023025850A2 publication Critical patent/BR112023025850A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

inibidores da nicotinamida ripk1. são descritos, no presente documento, compostos da fórmula (i) e sais farmaceuticamente aceitáveis dos mesmos, úteis como inibidores da ripk1, e composições farmacêuticas que compreendem os mesmos. são fornecidos adicionalmente métodos de uso e preparação.
BR112023025850A 2021-08-10 2022-08-08 Inibidores da nicotinamida ripk1 BR112023025850A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163231590P 2021-08-10 2021-08-10
PCT/US2022/039689 WO2023018643A1 (en) 2021-08-10 2022-08-08 Nicotinamide ripk1 inhibitors

Publications (1)

Publication Number Publication Date
BR112023025850A2 true BR112023025850A2 (pt) 2024-03-05

Family

ID=83439074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025850A BR112023025850A2 (pt) 2021-08-10 2022-08-08 Inibidores da nicotinamida ripk1

Country Status (13)

Country Link
US (1) US11767310B2 (pt)
EP (1) EP4301744A1 (pt)
JP (2) JP7406672B2 (pt)
KR (1) KR20230163568A (pt)
CN (1) CN117460722A (pt)
AR (1) AR126733A1 (pt)
AU (1) AU2022328136A1 (pt)
BR (1) BR112023025850A2 (pt)
CA (1) CA3219155A1 (pt)
CO (1) CO2023017151A2 (pt)
IL (1) IL308349A (pt)
TW (1) TW202321211A (pt)
WO (1) WO2023018643A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023018643A1 (en) 2021-08-10 2023-02-16 Abbvie Inc. Nicotinamide ripk1 inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005131A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New carboxamides with antifungal activity
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
ATE421512T1 (de) 2003-08-15 2009-02-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
US7112316B1 (en) 2005-08-08 2006-09-26 Uop Llc Process for preparing molecular sieves via continuous addition of nutrients
JP2009526747A (ja) 2006-02-16 2009-07-23 武田薬品工業株式会社 環状アミン化合物および高血圧の予防・治療のための用途
US8080542B2 (en) 2007-09-20 2011-12-20 Amgen, Inc. S1P receptor modulating compounds and use thereof
CN102036981B (zh) 2008-03-18 2015-04-08 默沙东公司 取代的4-羟基嘧啶-5-甲酰胺
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
EP2547724B1 (en) 2010-03-17 2015-11-11 ExxonMobil Chemical Patents Inc. Plasticiser blends and compositions and articles made therefrom
EA022582B1 (ru) 2010-10-20 2016-01-29 Грюненталь Гмбх Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
WO2013049255A1 (en) 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
EP3756666A1 (en) 2013-12-24 2020-12-30 Oncotartis Inc. Nicotinamide compound for use in the treatment of cancer
KR101555033B1 (ko) 2014-07-28 2015-09-23 충남대학교산학협력단 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
AU2015371822B2 (en) 2014-12-24 2020-04-09 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
US10787462B2 (en) 2015-10-23 2020-09-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
EP3515447A4 (en) 2016-09-26 2020-05-27 Tufts University NUCLEOSIDE URIDINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
DE102017211104B3 (de) 2017-06-29 2018-10-18 Bundesdruckerei Gmbh Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung
BR112020022420A2 (pt) 2018-05-03 2021-03-02 Rigel Pharmaceuticals, Inc. composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para produzir o composto
EP3795571B1 (en) 2018-07-02 2024-05-08 Shenzhen TargetRx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
US20210284647A1 (en) 2018-07-10 2021-09-16 Voronoibio Inc. N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases
KR20200089219A (ko) * 2019-01-15 2020-07-24 보로노이 주식회사 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
WO2023018643A1 (en) 2021-08-10 2023-02-16 Abbvie Inc. Nicotinamide ripk1 inhibitors

Also Published As

Publication number Publication date
TW202321211A (zh) 2023-06-01
EP4301744A1 (en) 2024-01-10
IL308349A (en) 2024-01-01
CA3219155A1 (en) 2023-02-16
US20230127127A1 (en) 2023-04-27
AU2022328136A1 (en) 2023-11-30
JP7406672B2 (ja) 2023-12-27
AR126733A1 (es) 2023-11-08
WO2023018643A1 (en) 2023-02-16
KR20230163568A (ko) 2023-11-30
JP2023549007A (ja) 2023-11-22
JP2024037892A (ja) 2024-03-19
US11767310B2 (en) 2023-09-26
CO2023017151A2 (es) 2023-12-29
CN117460722A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112016016844A2 (pt) Compostos heterocíclicos
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
BRPI0908120A8 (pt) Compostos que são inibidores de erk, composição faramacêutica e uso
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112022022608A2 (pt) Compostos como inibidores de bcl-2
BR112022006018A2 (pt) Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
BR112022006279A2 (pt) Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
BR112022018067A2 (pt) Aminas de pirrolopirimidina como inibidores de complemento
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta